American Gene Technologies, a clinical-stage biotechnology company, has appointed Jeff Boyle, PhD as chief science officer. Dr. Boyle comes to the post with deep biotechnology expertise which will help further accelerate the company’s FDA-approved HIV gene therapy clinical trial that expects to see first indications of efficacy in Q3, as well as continue the developments in monogenic disease and immuno-oncology.
Tanner Ash recently joined BioNTech as Senior Specialist, Quality Assurance Operations. Tanner was most recently a Supervisor at Ellume, a global diagnostics company that develops, manufactures, and commercializes the next generation of digitally enabled diagnostic products for healthcare professionals and consumers.
In addition to his work with Ellume, over the past decade Tanner has held positions with Kite, VaLogic, and Lonza.
Brian Stamper recently joined Immunomic Therapeutics, Inc. as Vice President, Cell Therapy Operations. Brian has over 20 years of experience in the biopharmaceutical industry, including increasingly responsible management positions in various operational areas including cell therapy operations, biotechnology manufacturing, and process engineering.
Former lab scientist Alexis Staten recently joined Workforce Genetics (WFGX) as a Life Sciences Recruiter. Alexis brings a unique background in customer service and lab experience to her new role. She joins an experienced, growing biopharma talent recruiting team at Workforce Genetics and joins Paul Streng, another recent hire, as a former scientist turned life sciences recruiter.
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, announced today that the company’s Board of Directors appointed Seth Van Voorhees, Ph.D. as Chief Financial Officer and Treasurer effective June 13, 2022.
Former scientist and veteran life sciences recruiter Paul Streng recently joined Workforce Genetics (WFGX) as a Senior Life Science Talent Consultant. Paul brings a wealth of diverse experience to his new role, including a successful executive recruiting track record coupled with deep experience as a lab supervisor, a field application scientist and a life science product manager and marketer.
At MSCRF, Ben is responsible for management and oversight of the research portfolio. In this role, Ben aspires to develop and support stem cell and regenerative medicine research in the state of Maryland by working with scientists and various stakeholders to promote commercialization of stem cell technologies for treating patients at the bedside.
The Center for Breakthrough Medicines (CBM) announced today the appointment of Joseph (Joe) Lingle as Chief People Officer. In his role, Lingle will oversee all Human Resources (HR) activities, including talent management, workplace experience, and Diversity, Equity, and Inclusion (DE&I).
Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, announced today that the board of directors and Bruce Goldsmith, Ph.D. have mutually agreed that Dr. Goldsmith will step down as president and chief executive officer and a member of the board, effective immediately. The board has appointed Edgar B. (Chip) Cale, the current general counsel and corporate secretary, as interim CEO. Dr. Goldsmith will serve as a strategic advisor to management and the board for a transition period.
Gilbane Building Company is pleased to announce that Jose Jimenez has joined the company as vice president and director of life sciences in Gilbane’s Mid-Atlantic division, based in the Philadelphia, PA office. In this role, Jose will support Gilbane’s life sciences clients across Pennsylvania, New Jersey, Maryland, Washington, DC and Virginia.
